Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 18, 2013British Journal of Clinical PharmacologyOpen Access

The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design

View Full Paper
Ask AI
Bookmark
Share

Authors

RTRuth ThompsonUniversity of SheffieldAEAlan EastmanDartmouth College

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Thompson et al. (2013) studied this question.

synapsesocial.com/papers/6a6fb7652163a0a01bc3fc59https://doi.org/10.1111/bcp.12139
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CHIR-124, a Novel Potent Inhibitor of Chk1, Potentiates the Cytotoxicity of Topoisomerase I Poisons <i>In vitro</i> and <i>In vivo</i>2007 · 151 citations
  2. 2The Chk1 Protein Kinase and the Cdc25C Regulatory Pathways Are Targets of the Anticancer Agent UCN-012000 · 541 citations